|Amgen Inc -- USA Stock|| |
USD 183.55 0.05 0.0272%
Executive Vice President - Research and Development
Dr. Sean E. Harper is the Executive Vice President Research and Development of Amgen Inc. Dr. Harper joined the Company in 2002, and has held leadership roles in early development, medical sciences and global regulatory and safety
Age: 53 President Since 2012 Ph.D
Harper served as Senior Vice President, Global Development and Corporationrationrationrate Chief Medical Officer from March 2007 to February 2012. Prior to joining the Company, Dr. Harper worked for five years at Merck Research Laboratories.
Sean Harper Latest Insider Activity
The company has return on total asset (ROA)
of 8.32 %
which means that it generated profit of $8.32 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE)
of 7.18 %
meaning that it created $7.18 on every $100 dollars invested by stockholders.
The company currently holds 35.34 B in liabilities with Debt to Equity (D/E) ratio of 140.0 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Amgen Inc has Current Ratio of 5.38 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California. Amgen operates under Biotechnology classification in USA and traded on NASDAQ exchange. It employs 20800 people.Amgen Inc (AMGN) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 20,800 people. Amgen is listed under Pharmaceutical Products category by Fama And French industry classification.